Travere Therapeutics, Inc.
TVTX
$62.05
$0.621.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 169.58M | 127.20M | 129.69M | 164.86M | 114.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 169.58M | 127.20M | 129.69M | 164.86M | 114.45M |
| Cost of Revenue | 69.52M | 83.86M | 60.42M | 53.48M | 64.52M |
| Gross Profit | 100.07M | 43.34M | 69.27M | 111.38M | 49.93M |
| SG&A Expenses | 96.11M | 80.25M | 101.69M | 86.45M | 62.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 165.63M | 164.11M | 162.12M | 139.93M | 127.10M |
| Operating Income | 3.95M | -36.92M | -32.43M | 24.93M | -12.65M |
| Income Before Tax | -35.00M | -36.72M | -21.07M | 25.71M | -12.74M |
| Income Tax Expenses | -204.00K | -120.00K | 921.00K | 8.00K | 20.00K |
| Earnings from Continuing Operations | -34.80M | -36.60M | -21.99M | 25.71M | -12.76M |
| Earnings from Discontinued Operations | -- | -500.00K | 24.72M | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.80M | -37.10M | 2.73M | 25.71M | -12.76M |
| EBIT | 3.95M | -36.92M | -32.43M | 24.93M | -12.65M |
| EBITDA | 8.19M | -11.70M | -14.29M | 40.72M | 1.37M |
| EPS Basic | -0.37 | -0.40 | 0.03 | 0.29 | -0.14 |
| Normalized Basic EPS | -0.23 | -0.25 | -0.15 | 0.18 | -0.09 |
| EPS Diluted | -0.37 | -0.40 | 0.03 | 0.28 | -0.14 |
| Normalized Diluted EPS | -0.23 | -0.25 | -0.15 | 0.16 | -0.09 |
| Average Basic Shares Outstanding | 93.48M | 91.87M | 90.29M | 89.23M | 88.95M |
| Average Diluted Shares Outstanding | 93.48M | 91.87M | 90.29M | 102.62M | 88.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |